Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Capecitabine in Refractory HER2+ Breast Cancer
NCT00078572Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2004
- Primary completion
- Apr 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of lapatinib in breast cancer (2 arms), sponsored by GSK. Primary endpoint: Time to progression. Started Mar 2004; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00078572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078572.